Myriad Genetics Affirms FY2026 Sales Guidance of $770.000M-$790.000M vs $776.790M Est

Benzinga Newsdesk www.benzinga.com Negative 78.9%

Neg 78.9% Neu 0% Pos 0%

Myriad Genetics (NASDAQ:MYGN) affirms FY2026 sales outlook from $770.000 million-$790.000 million to $770.000 million-$790.000 million vs $776.790 million estimate.